Patients with ER positive as well as ER negative breast cancer obtain improved survival from adjuvant polychemotherapy [17], but the benefit of chemotherapy is less in typical luminal A tumors with strong ER expression compared to other subtypes [18]. This evidence concerns the gene ESR1 and breast carcinoma.